Direct answer: The FDA published in August 2026 a draft “Determining whether to Submit an ANDA or a 505(b)(2) Application” to assist applicants in judging FD&C.Cc Which simplified approval path would be more suitable for its application for medicines. The draft revised the 2019 guide to add or clarify, inter alia, duplicate applications and ANDA qualifications; It is not yet a final guide and the deadline for the submission of comments was closed on 19 October 2026.The nature of the document, its current status and the enterprise recommendations are set out below; Specific products should be judged in the official language.

What is this file, at what stage?

The regulatory document and its status referred to in this paper is based on the original FDA page listing. (b) When the period for comments on the draft is over but the draft does not automatically become the final guide; Path eligibility shall be determined by statute, existing FDA documents and product facts.

A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.

Which enterprises and products need attention?

Applicants, imitators and regulatory teams are planning a simplified application path for small molecules in the United States.

It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.

Where is the change from what was previously requested?

The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.

Direct answer:The FDA published in August 2026 a draft “Determining whether to Submit an ANDA or a 505(b)(2) Application” to assist applicants in judging FD&C.Cc Which simplified approval path would be more suitable for its application for medicines. The draft revised the 2019 guide to add or clarify, inter alia, duplicate applications and ANDA qualifications; It is not yet a final guide, and the deadline for submission of comments was completed on 19 October 2026.

ANDA and 505(b)(2) are the routes for listing of medicines, not the registration of facilities or NDC listings. The path selection depends on the relationship between the product to be applied for and the reference drug, the data to be relied upon and the legal conditions to be applied; It cannot be judged solely on the basis of “simulating pharmaceuticals” or product names.

ANDA follows the 505(j) path, and the applicant is usually required to meet the statutory conditions relating to the approved reference drug; 505(b)(2) applications may rely on investigations or FDA determinations that the applicant has not conducted on his own initiative and that the applicant does not have the right to refer to, and to prepare appropriate information in the light of his or her particular differences. Specific equivalents, data references and qualification requirements should be consulted directly in the legislation and the FDA Guide.

  1. The active ingredient, agent type, specifications, route of delivery and labeling of the drug are to be developed.
  2. Potential reference drugs and their FDA approval status, orange Book information and market conditions.
  3. The formulation, the mode of delivery, the adaptive, the dosage or other differences from the reference.
  4. Public information to be relied upon, FDA identification, patent/exclusive period and research evidence.
  5. Product-specific issues are discussed through the formal communication mechanism of the FDA, where necessary.

The FDA page labels the 2026 version as Draft Level 1 Guide; The opinion period has been closed. The draft was intended to clarify the proposal made by the FDA at that time and was not a document that could be used directly as a final rule. Project decision-making should be accompanied by checks of existing legislation, the final 2019 guidelines, the status of the 2026 draft and the FDA follow-up update.

Key dates and transitional arrangements

The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.

  • August 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
  • 19 October 2026: Comments/due date of submission (as expressed in the original language of the neighbouring Government).

The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.

How can Chinese companies prepare?

  1. Re-assess the reference drug, the active ingredient/agent type/medication route, the rights base for which the information is to be relied, the differences and the required studies.
  2. Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
  3. If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.

For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.

Exceptions, pending confirmations and common misreading

  • (b) When the period for comments on the draft is over but the draft does not automatically become the final guide; Path eligibility shall be determined by statute, existing FDA documents and product facts.
  • When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
  • Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.

Official information and reconciliation records

(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.

Next

Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.